irs program accomplishments · form 990 part iii · fy2023
What they reported doing
- #1 primary $1.24MPUBLIC EDUCATION AND INFORMATION PROGRAM: THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD, FUNDING PREEMINENT PANCREATIC CANCER RESEARCHERS, DRIVING THE PURSUIT OF BOLD AND INNOVATIVE SCIENCE TOWARD EARLIER DETECTION AND BETTER TREATMENTS, AND TRANSFORMING PANCREATIC CANCER INTO A CURABLE DISEASE. THE FOUNDATION FUNDS RESEARCH WHERE CREATIVE RISKS YIELD HIGH REWARDS TO ACCELERATE AND EXPAND LIFE-SAVING TREATMENT OPTIONS. WE BELIEVE TIME IS EVERYTHING TO PATIENTS AND THEIR FAMILIES, AND THAT COMMUNITY IS POWER. LUSTGARTEN PROGRAMS AND EVENTS PROVIDE PEOPLE AFFECTED BY PANCREATIC CANCER A VOICE AND A PLACE TO CREATE HOPE, TOGETHER. SEE SCHEDULE O.
- #2 $757KPROFESSIONAL EDUCATION PROGRAM: PROFESSIONAL EDUCATION FOCUSED ON THE FOUNDATION'S SENIOR LEADERSHIP CONDUCTING HIGH-LEVEL MEETINGS WITH FUNDED SCIENTISTS AND DIRECTORS OF THE LABS PROGRAM SITES AND COLLABORATING ORGANIZATIONS, AS WELL AS ATTENDING/PRESENTING AT SCIENTIFIC MEETINGS. SEE SCHEDULE O.
named programs · 5 · from sources
What they call their work
Cancer of the Pancreas Screening (CAPS) Study
National multi-center study led by Johns Hopkins to detect pancreatic cancer and precursor lesions in individuals with inherited risk.
Let’s Win! Pancreatic Cancer
Affiliate initiative providing a community platform for patients, doctors, and scientists to share treatment options, support resources, and clinical trial information.
Lustgarten Advancing Breakthrough Science (LABS) Program
Funds dedicated pancreatic cancer research laboratories at Cold Spring Harbor Laboratory, MIT, Dana-Farber Cancer Institute, Salk Institute, and Johns Hopkins.
PASS (Pancreatic Adenocarcinoma Signature Stratification for Treatment) Trial
Clinical trial integrating genomic profiling, RNA subtyping, and patient-derived organoids to guide personalized treatment for metastatic pancreatic cancer.
Pancreatic Cancer Collective
Joint initiative with Stand Up To Cancer to accelerate research and improve outcomes for pancreatic cancer patients through collaborative funding and clinical trials.
activities · 3 groups
What they do
-
Pancreatic Cancer Research and Support 6 activities
- Establishes and funds dedicated research laboratories (LABS Program)Established the Lustgarten Advancing Breakthrough Science (LABS) Program, funding dedicated pancreatic cancer research laboratories at Cold Spring Harbor Laboratory, MIT, Dana-Farber Cancer Institute, Salk Institute, and two sites at Johns Hopkins. Includes a 2,200 sq ft organoid facility supporting clinical trials.
- Facilitates national collaboration and shapes research agendaPlays a key role in shaping the national agenda for pancreatic cancer research, including through the National Cancer Institute’s first Pancreatic Cancer Progress Review Group and by increasing NCI funding to over $182.1 million by 2018. Promotes collaboration among world-renowned researchers.
- Funds and conducts high-risk, high-reward pancreatic cancer researchHas invested over $301 million in pancreatic cancer research, funding high-impact projects including the Pancreatic Cancer Genome Project, development of Abraxane as standard of care, and FDA approval of Keytruda® for a specific mutation. Supports research across early detection, therapeutic development, and personalized medicine.
- Implements personalized medicine programs for pancreatic cancerCharacterizes tumor heterogeneity and develops decision-support tools to match patients with optimal treatments. Funded the COMPASS study, which identified molecular subtypes of pancreatic cancer, enabling tailored therapeutic strategies.
- Supports early detection and pre-cancer intervention researchDevelops tools and methods for early diagnosis, including biomarker optimization, risk assessment, and interception strategies for high-risk individuals. Co-created the CAPS study, the first multi-center national study to detect pancreatic cancer and precursor lesions in high-risk populations.
- Supports individual researcher grants to advance pancreatic cancer scienceProvides targeted grants to promising researchers, including a $300,000 award to Michael Goggins, MD, and a $700,000 grant to Elizabeth Jaffee, MD, to launch or advance their pancreatic cancer research careers.
-
-
Cancer Research Funding 1 activity
- Advances preclinical and clinical testing of novel therapiesIdentifies new drug targets based on cancer biology and advances preclinical and clinical testing of novel drugs, drug combinations, surgical techniques, and ablative therapies. Funded research leading to FDA-approved treatments and supports trials such as the PASS (01) Trial using patient-derived organoids.
-
-
Biomedical Research and Innovation 1 activity
- Builds and sustains a multidisciplinary pancreatic cancer research communitySupports the growth of a research community of thousands of scientists across disciplines. Operates with oversight from scientific, corporate, and board leadership to advance discovery and translation.
-
financials · form 990 · fy2023
revenue
Total revenue$22.75M
Contributions & grants$21.13M93%
Program service revenue$00%
Investment income$1.27M6%
Other revenue$348K
expenses
Total expenses$30.96M
Program expenses83%
Admin / overhead7%
Fundraising10%
Salaries & benefits$4.67M
Grants paid out$21.88M
Largest expense lineCompensation
balance sheet
Total assets$75.80M
Cash$3.90M
Investments$68.97M
Liabilities$10.92M
Net assets$64.88M
Liquid reserves28.2 mo
5 years on record · 2019–2023 · YoY revenue +24.3%
leadership · form 990 part vii · fy2023
Who runs it
paid leadership · 8
| Name | Title | Hours/wk | Compensation |
|---|---|---|---|
| LINDA TANTAWI | CEO | 40 | $521K |
| KERRI KAPLAN | PRESIDENT | 40 | $378K |
| GLEN PECK | SVP TECHNOLOGY & BUSINESS INTELLIGENCE | 40 | $322K |
| ANDREW RAKEMAN | VP RESEARCH | 40 | $311K |
| FAISAL JAWAID | CFO | 40 | $305K |
| STEPHANIE DERGARABEDIAN | NATIONAL DIRECTOR OF DEVELOPMENT | 40 | $204K |
| JACLYN P LYMAN | HEAD CLINICAL RESEARCH & DEVELOPMENT | 40 | $198K |
| SUSAN M JACOBSON | DIRECTOR EXTERNAL & COMMUNITY RELATIONS | 40 | $194K |
board members · 17
- AARON KANTOFF — DIRECTOR (AS OF 6/7/2024)
- ADAM SILVER — VICE CHAIRMAN
- ANDREW LUSTGARTEN — CHAIRMAN
- CHARLES F DOLAN — CHAIRMAN EMERITUS (END 3/31/24)
- CHARLES R SCHUELER — DIRECTOR
- JAMES L DOLAN — VICE CHAIRMAN (END 3/31/24)
- JENNIE FORTUNOFF — SECRETARY
- JESSICA LUSTGARTEN COURTEMANCHE — DIRECTOR
- JOHN H COBB — DIRECTOR
- MARCIA LUSTGARTEN — DIRECTOR
- PHILIP D'AMBROSIO — TREASURER
- QUENTIN F DOLAN — TRUSTEE (END 3/31/24)
- RICHARD R BARAKAT MD MBA — DIRECTOR (AS OF 6/7/2024)
- ROBERT F VIZZA — CHAIRMAN EMERITUS
- SCOTT PENBERTHY — DIRECTOR
- SELWYN VICKERS — DIRECTOR
- SHEILA MAHONY — DIRECTOR
relationships · 37
Who they work with
- BIDMC Partner — Ted Hong is affiliated with BIDMC and serves on the Scientific Advisory Board.
- Cablevision Partner — Co-founded in partnership with Cablevision leadership, including Chairman Charles F. Dolan and CEO James L. Dolan.
- Cedars Sinai Medical Center Partner — Cristina Ferrone is affiliated with Cedars Sinai Medical Center and serves on the Translational Advisory Group.
- Cold Spring Harbor Laboratory Partner — Established and funded the Lustgarten Foundation Pancreatic Cancer Research Laboratory at Cold Spring Harbor Laboratory.
- Cold Spring Harbor Laboratory Partner — Hosts the Lustgarten Distinguished Lab for pancreatic cancer research.
- Cold Spring Harbor Laboratory Cancer Center Partner — Hosts David Tuveson, who serves as Chief Scientist of the Lustgarten Foundation.
- DFCI Partner — Brian Wolpin is affiliated with DFCI and serves on the Translational Advisory Group.
- Dana-Farber Cancer Institute Partner — Funded a LABS research program at Dana-Farber Cancer Institute.
- Dana-Farber Cancer Institute Partner — Hosts a Lustgarten Distinguished Lab focused on pancreatic cancer research.
- Dana-Farber Cancer Institute Partner — Ted Hong is affiliated with Dana-Farber Cancer Institute and serves on the Scientific Advisory Board.
- Exact Sciences Partner — Funded early development of CancerSEEK, a multi-cancer blood test later acquired and advanced by Exact Sciences for FDA approval.
- Harvard Medical School Partner — Ted Hong is a professor at Harvard Medical School and serves on the Scientific Advisory Board.
- Johns Hopkins Partner — Elizabeth M. Jaffee, affiliated with Johns Hopkins, serves as Chief Medical Advisor of the Lustgarten Foundation.
- Johns Hopkins Partner — Funded multiple research initiatives at Johns Hopkins, including the CAPS study, work by Michael Goggins and Elizabeth Jaffee, and the first-in-human prevention vaccine trial.
- Keytruda Partner — Funded research that contributed to Keytruda® becoming the first FDA-approved immunotherapy for advanced pancreatic cancer patients with a specific mutation.
- Koch Institute for Integrative Cancer Research Partner — Lustgarten Foundation supports pancreatic cancer research at the Koch Institute through its Distinguished Lab program.
- Let’s Win Pancreatic Cancer Partner — Collaborates with Let’s Win Pancreatic Cancer to share research updates and engage the community.
- Let’s Win! Pancreatic Cancer Partner — Created Let’s Win! Pancreatic Cancer as an affiliate to connect patients, doctors, and scientists for shared information on treatment and clinical trials.
- MIT Partner — Funded a LABS research program at MIT as part of the Lustgarten Advancing Breakthrough Science initiative.
- MIT Partner — Tyler Jacks is affiliated with MIT's Koch Institute and serves on the Scientific Advisory Board.
- Massachusetts Institute of Technology Partner — Hosts the Koch Institute, where the Lustgarten Distinguished Lab conducts pancreatic cancer research.
- Memorial Sloan Kettering Cancer Center Partner — Luis Diaz is affiliated with Memorial Sloan Kettering Cancer Center and serves on the Scientific Advisory Board.
- NYU Langone Health Partner — Dafna Bar-Sagi, affiliated with NYU Langone Health, serves as Chief Science Officer of the Lustgarten Foundation.
- National Cancer Institute Government — Collaborates indirectly by stimulating increased federal funding for pancreatic cancer research.
- National Cancer Institute Partner — Collaborated with the National Cancer Institute to support the CAPS study and co-develop national research agendas for pancreatic cancer.
- OHSU Partner — Lisa Coussens is affiliated with OHSU and serves on the Translational Advisory Group.
- Princess Margaret Cancer Centre Partner — Jennifer Knox is affiliated with Princess Margaret Cancer Centre and serves on the Translational Advisory Group.
- Salk Institute Partner — Funded a LABS research program at the Salk Institute.
- Salk Institute for Biological Studies Partner — Laboratory site for the Shaw Lab, supported by the Lustgarten Foundation.
- Salk Institute for Biological Studies Partner — Reuben Shaw is affiliated with the Salk Institute and serves on the Scientific Advisory Board.
+ 7 more
strategies · 4
How they approach the work
Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.
- Early Detection and Interceptionmethodology: early_detection_and_interceptionBy detecting pancreatic cancer earlier through biomarker development and intervening at the pre-cancer stage in high-risk individuals, the foundation prevents advanced disease, because early interception fundamentally shifts outcomes by acting before tumors become inoperable.
- Interdisciplinary Collaborative Sciencemethodology: collaborative_research_networkBy integrating expertise across biology, engineering, and clinical science and fostering collaboration among top researchers, the foundation accelerates discovery, because interdisciplinary and cooperative models break down silos and enable faster, more innovative solutions.
- Personalized Medicine via Organoid Modelingmethodology: precision_medicine_via_organoid_modelingBy using patient-derived organoids to test drug responses in the lab, the foundation enables tailored treatment decisions and accelerates clinical research, because modeling individual tumor biology improves therapeutic precision and reduces trial-and-error in care.
- Translational Research Pipelinemethodology: bench-to-bedside_translationBy systematically advancing laboratory discoveries through the research pipeline into clinical testing and patient care, the foundation accelerates the development of new therapies and early detection methods, because bench-to-bedside translation closes the gap between scientific innovation and real-world impact.